Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
GYRE has been in the news recently: Senhwa Biosciences has submitted an IND application for its cancer drug Pidnarulex to the U.S. FDA, intending to conduct trials over the next five years with the NCI. Additionally, Anixa Biosciences plans to present its CAR-T therapy for recurrent ovarian cancer at the OCRA conference in September 2024.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
